| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 35.8 | 44.4 |
| Gross profit | 9.8 | 12.4 |
| Profit before tax | -6.4 | -8.5 |
| Net income | -6.4 | -8.5 |
| EPS (diluted, $ a share) | $-0.31 | $-0.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -19.4% |
|---|---|
| Gross margin | 27.4% |
| Operating margin | -17.9% |
10-Q filed with the SEC, NASDAQ: PETS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Petmed Express Inc: key numbers
- Share price
- $0.8977Close, Nov 16
- Market cap
- $20M
- Shares outstanding
- 22.23MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Retail-Drug Stores and Proprietary StoresSIC 5912
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Petmed Express Inc
All →Petmed Express Financial Results
PetMed Express reported second quarter fiscal year 2027 net sales of $35.8 million, a 19.4% decrease year-over-year driven by lower prescription sales. The company narrowed its net loss to $6.4 million compared to $8.5 million in the prior year, aided by reduced general, administrative, and advertising expenses. CEO Jeff Willard noted the company is focused on stabilizing operations and reducing customer acquisition costs, which fell 32% from the previous year.
- Term
- Q2 2027
“We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today.”
Jeff Willard, Chief Executive Officer and President of PetMeds
“We are already making progress: this quarter we cut our cost to acquire a new customer by 32% from a year ago. Next, we are repositioning the brand so pet parents know exactly why to choose PetMeds, making our marketing work harder, making our website easier to buy from, and keeping more of the customers we win.”
Jeff Willard, Chief Executive Officer and President of PetMeds
Petmed Express Stock Plan Amendment
PetMed Express amended its 2024 Inducement Incentive Plan to increase the number of shares reserved for issuance by 500,000 shares, bringing the total to 850,000. This increase is specifically intended to cover equity grants for the company's new CEO, Jeffrey Allen Willard, consisting of 250,000 shares of restricted stock and 250,000 performance share units.
Petmed Express Leadership Change
PetMed Express appointed Tamar Elkeles, Ph.D., to its Board of Directors, effective September 17, 2026, increasing the board size to five members. Dr. Elkeles, an independent director with over 30 years of experience in human capital and technology, will serve as Chair of the Compensation and Human Capital Committee. The appointment is part of the company's ongoing board refreshment and follows a recent executive leadership transition.
- Counterparty
- Tamar Elkeles
Petmed Express Executive Compensation
PetMed Express has appointed Jeffrey Allen Willard as its new CEO and President, effective September 28, 2026, succeeding interim CEO Leslie C.G. Campbell. Under his employment agreement, Willard will receive an annual base salary of $550,000, a $120,000 signing bonus, and a $50,000 relocation allowance. Additionally, Justin Mennen will succeed Campbell as Chair of the Board following her retirement.
- Counterparty
- Jeffrey Allen Willard
- Term
- 3 years